Skip to main content
Clinical Trials/NCT02297581
NCT02297581
Completed
Not Applicable

A Prospective Multicenter Cohort Study to Evaluate the Benefit of the Geriatric Fracture Center (GFC) Concept

AO Innovation Translation Center12 sites in 6 countries282 target enrollmentMay 2015
ConditionsHip Fractures

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hip Fractures
Sponsor
AO Innovation Translation Center
Enrollment
282
Locations
12
Primary Endpoint
Major Adverse Events related to treatment / residential status / immobilization
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The study will assess patients with at least one major AE related to treatment / hospitalization / immobilization in the Geriatric Fracture Center (GFC) group compared to the usual care group.

Detailed Description

Patients aged ≥ 70 years or older with an osteoporotic hip fracture treated with an osteosynthesis or endoprosthesis will be included in this study. The primary objective of the study is to assess the difference in the numbers of pre-defined major adverse events (AE) which are related to the treatment, hospitalization and/or immobilization between patients who were treated in a geriatric fracture center or in a usual care center. As a secondary objective, health economic implications and cost-effectiveness comparison analyses will be performed. In order to be able to analyze data based on the geographic regions as well as globally, in each participating country, both a Geriatric Fracture Center (GFC) and a Usual Care Center (UCC) will be included.

Registry
clinicaltrials.gov
Start Date
May 2015
End Date
May 2020
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
AO Innovation Translation Center
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 70 years
  • Geriatric patients with hip fractures Treated either with oOsteosynthesis or oEndoprosthesis
  • Ability of the patient or assigned representative to understand the content of the patient information / Informed Consent Form
  • Signed and dated Institutional Review Board (IRB) / Ethics Committee (EC)-approved written informed consent
  • Preoperative

Exclusion Criteria

  • Recent history of substance abuse (ie, recreational drugs, alcohol) that would preclude reliable assessment
  • Participation in any other medical device or medicinal product study within the previous month that could influence the results of the present study

Outcomes

Primary Outcomes

Major Adverse Events related to treatment / residential status / immobilization

Time Frame: From surgery up to 1 year follow-up

Major AEs related to treatment / residential status / immobilization: * Delirium * Congestive heart failure * Pneumonia * Deep venous thrombosis * Pulmonary embolism * Pressure ulcers * Myocardial infarction

Secondary Outcomes

  • Time from admission to surgery(Baseline (admission to surgery), about 1-2 days)
  • Direct and indirect costs(Baseline up to 1 year follow-up)
  • Time from admission to start of pain medication(Baseline (admission to surgery), about 1-2 days)
  • Any other AEs not mentioned under primary outcome measure(s) as well as its relationship to the treatment / residential status / immobilization(From surgery up to 1 year follow-up)
  • Timed up and go test (TUG)(12 weeks and 1 year follow-up)
  • Parker Mobility Score(Baseline, 12 weeks and 1 year follow-up)
  • Quality of Life(12 weeks and 1 year postoperative)
  • Residential status(Baseline up to 1 year follow-up)
  • Falls(From surgery up to 1 year follow-up)
  • Number of patients receiving adequate secondary fracture prevention(Baseline up to 1 year follow-up)
  • Number of patients for which the nutrition status was evaluated / adapted(Baseline (admission to discharge), about 1-2 days)
  • Activities of daily living(Baseline, 12 weeks and 1 year postoperative)
  • Number of re-admissions to an acute hospital(From surgery up to 1 year follow-up)
  • Mortality(From surgery up to 1 year follow-up)
  • Pain(From surgery up to1 year follow-up)
  • Occurrence of a contralateral hip fracture(Retrospective assessment of pre-injury status up to 1 year follow-up)
  • Time from admission to start of fluid management(Baseline (admission to surgery), about 1-2 days)
  • Time from surgery to discharge 1 and 2(Baseline (admission to discharge), about 1-2 weeks)
  • Medication(Baseline up to 1 year follow-up)

Study Sites (12)

Loading locations...

Similar Trials